RxDoctor Payments DataLook up a doctor →

Keith Krawiec, MD

Internal Medicine · Louisville, KYNPI 1730186545

Payments from drug & device makers

$16,665in general payments, 2019–2025

Across 632 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • GSK$1K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • plus $9K from 43 others

What the payments were for

  • Food & beverage$16,627100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,665 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$187,074
Medicare patients
408
Services billed
1,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$88,851
XareltoRivaroxaban43$59,417
JardianceEmpagliflozin56$57,023
OzempicSemaglutide35$53,018
TrulicityDulaglutide13$30,318
JanuviaSitagliptin Phosphate28$26,410
PancreazeLipase/Protease/Amylase11$13,445
Repatha SureclickEvolocumab20$10,839
VascepaIcosapent Ethyl21$9,376
Rosuvastatin Calcium510$5,648
Atorvastatin Calcium728$5,431
SynthroidLevothyroxine Sodium73$4,440
Losartan Potassium410$3,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,053
Ezetimibe107$2,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$771$90,281107 claims
Johnson & JohnsonXarelto$1,059$59,41743 claims
Boehringer IngelheimJardiance$655$57,02356 claims
Novo NordiskOzempic$1,146$53,01835 claims
Lilly USA, LLCTrulicity$819$30,31813 claims
MerckJanuvia$194$26,41028 claims
Vivus LLCPancreaze$64$13,44511 claims
AbbVieSynthroid$1,126$4,44073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →